Author

W. Sol

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

J. Jonkers· 2 shared M. van de Ven· 2 shared S. Rottenberg· 2 shared A. Duarte· 1 shared A. Gasparini· 1 shared A. Kersbergen· 1 shared A. Kucukosmanoglu· 1 shared B. Morris· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Jonkers

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

J. Bhin, M. Paes Dias, E. Gogola, F. Rolfs, S. R. Piersma, R. de Bruijn, J. de Ruiter, B. van den Broek, A. Duarte, W. Sol, I. van der Heijden, L. Bakker, T. S. Kaiponen, C. Lieftink, B. Morris, , J. Jonkers

bioRxiv · Sep 7, 2022Cancer Biology

Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors

M. Barazas, A. Gasparini, Y. Huang, A. Kucukosmanoglu, S. Annunziato, P. Bouwman, W. Sol, A. Kersbergen, N. Proost, M. van de Ven, J. Jonkers, G. Borst, S. Rottenberg

This study identifies radiotherapy as a therapeutic target for BRCA1-deficient tumors that have developed resistance to PARP inhibitors through 53BP1 pathway inactivation.

bioRxiv · Jul 17, 2018Cancer Biology